Sonrotoclax (BGB-11417) in Relapsed or Refractory Mantle Cell Lymphoma: Early Findings From a Phase I/II Study
Sonrotoclax (BGB-11417) is a next generation, highly selective B-cell lymphoma 2 (BCL-2) inhibitor under investigation for patients with relapsed or refractory mantle cell lymphoma (R/R...
